CABALETTA BIO INC. -

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

22 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

10 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases

11 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

06 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference

26 сен 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

10 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

06 сен 2022 08:00:04 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

29 авг 2022 13:58:30 Источник Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

11 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

18 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference

17 май 2022 08:00:04 Источник Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

12 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference

06 апр 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

17 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

01 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

28 фев 2022 08:00:02 Источник Nasdaq GlobeNewswire

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

11 янв 2022 08:00:02 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

10 янв 2022 08:00:04 Источник Nasdaq GlobeNewswire

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

14 дек 2021 07:00:00 Источник Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

09 ноя 2021 16:30:00 Источник Nasdaq GlobeNewswire